NCT05185505 is a Phase 4 clinical trial of Atezolizumab in Hepatocellular Carcinoma, sponsored by The Methodist Hospital Research Institute.

Who is sponsoring NCT05185505?

NCT05185505 is sponsored by The Methodist Hospital Research Institute.

What drugs are being tested in NCT05185505?

Interventions in NCT05185505: Atezolizumab, Bevacizumab.

What condition does NCT05185505 study?

NCT05185505 studies Hepatocellular Carcinoma, Hepatocellular Cancer.

Is NCT05185505 still recruiting?

NCT05185505 is currently recruiting now. Last updated 1 February 2023.

Last reviewed 2023-02-01 · How we verify

NCT05185505

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Atezolizumab and Bevacizumab Pre-Liver Transplantation for Patients With Hepatocellular Carcinoma Beyond Milan Criteria

Recruiting now Phase 4 Last updated 1 February 2023

What this trial tests

Phase 4 trial testing Atezolizumab in Hepatocellular Carcinoma in 24 participants. Currently enrolling.

Timeline

30 January 2023

Primary endpoint
30 April 2027

31 October 2027

Quick facts

Lead sponsor	The Methodist Hospital Research Institute
Phase	Phase 4
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	24
Start date	30 January 2023
Primary completion	30 April 2027
Estimated completion	31 October 2027
Sites	1 location across United States

Drugs / interventions tested

Atezolizumab (atezolizumab) — full drug profile →
Bevacizumab (Bevacizumab-Bvzr) — full drug profile →

Conditions studied

Hepatocellular Carcinoma — all drugs for Hepatocellular Carcinoma →
Hepatocellular Cancer — all drugs for Hepatocellular Cancer →

Sponsor

The Methodist Hospital Research Institute

Who can join

18 and older, any sex, with Hepatocellular Carcinoma or Hepatocellular Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Patients with hepatocellular carcinoma (HCC) beyond Milan Criteria (MC) who are transplant-eligible will be treated with 6 months of neoadjuvant/downstaging atezolizumab plus bevacizumab while receiving standard of care transarterial chemoembolization (TACE). We hypothesize that atezolizumab and bevacizumab can appropriately bridge patients with HCC beyond MC to transplantation and not increase the risk of 1-year post-transplant rejection.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

The Evasion Mechanisms of Cancer Immunity and Drug Intervention in the Tumor Microenvironment.
Kim SK, Cho SW. · · 2022 · cited 300× · PMID 35685630 · DOI 10.3389/fphar.2022.868695
Immunotherapy as a Neoadjuvant Therapy for a Patient with Hepatocellular Carcinoma in the Pretransplant Setting: A Case Report.
Abdelrahim M, Esmail A, Umoru G, Westhart K, et al · · 2022 · cited 41× · PMID 35735450 · DOI 10.3390/curroncol29060341
Immunotherapy and Liver Transplantation: A Narrative Review of Basic and Clinical Data.
Wassmer CH, El Hajji S, Papazarkadas X, Compagnon P, et al · · 2023 · cited 35× · PMID 37760542 · DOI 10.3390/cancers15184574
Utilization of Immunotherapy for the Treatment of Hepatocellular Carcinoma in the Peri-Transplant Setting: Transplant Oncology View.
Abdelrahim M, Esmail A, Saharia A, Abudayyeh A, et al · · 2022 · cited 34× · PMID 35406533 · DOI 10.3390/cancers14071760
Immunotherapy in liver cancer: overcoming the tolerogenic liver microenvironment.
Liu Y, Yang H, Li T, Zhang N. · · 2024 · cited 23× · PMID 39295859 · DOI 10.3389/fimmu.2024.1460282
Neoadjuvant systemic therapy for hepatocellular carcinoma.
Chick RC, Ruff SM, Pawlik TM. · · 2024 · cited 16× · PMID 38495884 · DOI 10.3389/fimmu.2024.1355812
Transplant oncology - Current indications and strategies to advance the field.
Krendl FJ, Bellotti R, Sapisochin G, Schaefer B, et al · · 2024 · cited 15× · PMID 38304238 · DOI 10.1016/j.jhepr.2023.100965
Hepatocellular Carcinoma: The Role of Immunotherapy and Transplantation in the Era of Transplant Oncology.
Alghamdi S, Al-Hamoudi W. · · 2023 · cited 8× · PMID 37958291 · DOI 10.3390/cancers15215115

Verify or expand the search:

Other trials of Atezolizumab

Trials testing the same drug.

NCT07388524 — Testing the Impact of an Anti-Cancer Drug, Atezolizumab, After Surgery to Prevent Early Stage Non-small Cell Lung Cancer · Phase 3 · not yet recruiting
NCT07322341 — SX-682 and Atezolizumab for the Treatment of Advanced or Metastatic, Recurrent Non-small Cell Lung Cancer · Phase 2 · not yet recruiting
NCT07339059 — Phase II Study of Sacituzumab Govitecan With Atezolizumab/Durvalumab as Maintenance Therapy for Extensive-Stage Small Ce · Phase 2 · recruiting
NCT07461675 — Effects of Neoadjuvant Immunotherapy on Anti-tumour Immunity in Hepatocellular Carcinoma Patients Undergoing Liver Resec · Phase 3 · not yet recruiting
NCT07291076 — A Study to Evaluate the Safety and Tolerability of Pumitamig Alone or In Combination With Ipilimumab in Participants Wit · Phase 1, PHASE2 · recruiting

Other recruiting trials for Hepatocellular Carcinoma

Currently open trials in the same condition.

NCT06902246 — Regorafenib and Yttrium-90 Radioembolization for Unresectable Hepatocellular Carcinoma · Phase 2 · recruiting
NCT05842174 — Targeting Ischemia-Induced Autophagy Dependence in Hepatocellular Carcinoma · Phase 1, PHASE2 · recruiting
NCT07417397 — Adjuvant TACE in HCC With High-risk Recurrence Factors · Phase 3 · recruiting
NCT07317414 — β-alanine in the Treatment of Advanced Hepatocellular Carcinoma · Phase 2 · recruiting
NCT07148050 — Immunotherapy for Solid Tumor Malignancies in Pediatrics Using Interleukin-15 and -21 Armored Glypican-3-specific Chimer · Phase 1 · recruiting

Other The Methodist Hospital Research Institute trials

Trials by the same sponsor.

NCT07048314 — Stem Cells for Erectile Dysfunction Post RALP · Phase 1, PHASE2 · not yet recruiting
NCT07283068 — IO Vancomycin Into the Medial Malleolus vs IV Administration in Revision TKA · NA · not yet recruiting
NCT07218484 — VoiceLove Digital Therapy for Delirium in the ICU · NA · recruiting
NCT07050771 — Comprehensive Multimodal Prehabilitation Alone or With Neoadjuvant Therapy Before Major Cancer Surgery · Phase 2 · recruiting
NCT07182279 — Neoadjuvant High Dose Rate Brachytherapy Prior to Radical Prostatectomy in Patients With Prostate Cancer · Phase 1, PHASE2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05185505 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by The Methodist Hospital Research Institute
Last refreshed: 1 February 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05185505.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing